Diabetes & Endocrinology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

This Phase 3 study tested a new oral medication called orforglipron in adults with type 2 diabetes who are also overweight or have obesity and are at higher risk for heart problems. The trial compared orforglipron to insulin glargine, which is an injectable insulin treatment. If successful, orforglipron could offer a simpler, once-daily pill that may improve convenience and quality of life for people managing type 2 diabetes along with weight-related health challenges.

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

This ongoing Phase 3 trial is studying enicepatide, a new medication designed to help adults with obesity or overweight who also have type 2 diabetes. The goal is to see if enicepatide can better control blood sugar levels while also helping reduce body weight. The study is recruiting participants in several countries and will assess results after about 72 weeks of treatment, potentially offering a new option for managing both weight and diabetes together.

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Vertex Pharmaceuticals is conducting this Phase 3 trial to test VX-880, a cell therapy, in adults with type 1 diabetes who experience severe low blood sugar episodes and have difficulty sensing those drops. VX-880 aims to reduce dangerous low blood sugar events and may lessen the need for insulin injections. The study is still recruiting worldwide and hopes to improve safety and quality of life for people living with type 1 diabetes.

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

This Phase 3 study is evaluating retatrutide, a new drug for adults who are overweight or have obesity but do not have type 2 diabetes. The treatment is designed to help reduce body weight more effectively than current options. The study is recruiting in the United States and the United Kingdom and will last about 65 weeks. If successful, retatrutide could provide an important new tool for weight management.

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

This Phase 3 trial is testing baricitinib, an oral drug, in children and adults recently diagnosed with type 1 diabetes. The goal is to preserve the function of beta cells, which produce insulin naturally in the body. Maintaining beta cell activity could improve how well the disease is managed and potentially reduce the need for insulin injections over time. The study is recruiting globally and is expected to last around 60 weeks.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.